Fluocinonide Cream UPS, 0.05% (Emulsified Base), packaged in 60 g tube, Rx only, Mfd. by: Taro Ph...
FDA Drug Recall #D-0790-2017 — Class III — March 17, 2017
Recall Summary
| Recall Number | D-0790-2017 |
| Classification | Class III — Low risk |
| Date Initiated | March 17, 2017 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Taro Pharmaceuticals U.S.A., Inc. |
| Location | Hawthorne, NY |
| Product Type | Drugs |
| Quantity | 7,776 tubes |
Product Description
Fluocinonide Cream UPS, 0.05% (Emulsified Base), packaged in 60 g tube, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada, Dist. by Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532, NDC 51672-1254-3
Reason for Recall
Cross contamination with other products: Certain lots of Fluocinonide Cream were found to be contaminated with a small quantity of hydrocortisone-17-valerate.
Distribution Pattern
U.S. Nationwide
Lot / Code Information
Lot #: D301311473, D301411473, Exp 3/2017
Other Recalls from Taro Pharmaceuticals U.S.A., Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0633-2024 | Class III | Hydrocortisone 1% & Acetic Acid 2% Otic Solutio... | Aug 7, 2024 |
| D-0727-2022 | Class III | Clotrimazole and Betamethasone Dipropionate Cre... | Feb 25, 2022 |
| D-0375-2022 | Class I | Clobetasol Propionate Ointment USP, 0.05%, 60g ... | Dec 15, 2021 |
| D-0246-2021 | Class II | Nortriptyline HCl Capsules, USP equivalent to 1... | Jan 8, 2021 |
| D-0156-2021 | Class II | RiteAid Pharmacy RIngworm Cream, Clotrimazole C... | Nov 17, 2020 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.